The AI model analyzes three biomarkers from routine breast cancer hematoxylin and eosin-stained slides to predict breast cancer status. The tool helps physicians and researchers better understand the links between biological factors for treatment and the tumor, an Aug. 11 news release on the study said.
Treatment plans for breast cancer rely on identifying biomarkers. The algorithm interprets the slides and predicts biomarkers to help physicians determine treatment plans quicker.
The model will eventually be used to help physicians determine a tumor’s histology and microscopic structure.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
